|
Regeneron Gains Full Rights to Ophthalmology Antibodies from Sanofi
Genetic Engineering News Regeneron acquired full exclusive rights to two families of antibodies invented at the company’s labs, but previously included in its antibody collaboration with Sanofi. Acquired by Regeneron were full rights to antibodies targeting the PDGF (platelet … |
 iStockAnalyst |
Sanofi lets go of rights to Regeneron’s antibodies in ophthalmology
FierceBiotech The deal amends the collaboration between Sanofi and Regeneron for the antibodies that target receptors for platelet-derived growth factor (PDGF) and the angiopoietin2 (ANG2) receptor and ligand for eye ailments. Regeneron has agreed to pay Sanofi $10 … Regeneron Gains Full Rights to Ophthalmology Antibodies from Sanofi in $65M+ …Genetic Engineering News Regeneron Acquires Rights to Two Families of Novel AntibodiesBenzinga UPDATE 1-Regeneron raises 2013 Eylea sales view, profit beats StreetReuters UK RTT News –iStockAnalyst (press release) –Reuters all 23 news articles » |
|
Regeneron Acquires Rights to Two Families of Novel Antibodies
Benzinga Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it has expanded its ophthalmology portfolio by acquiring full exclusive rights to two families of novel antibodies invented at Regeneron and previously included in Regeneron’s … |
|
Liderança da Biogen Idec na Esclerose Múltipla reafirmada em Congresso nos …
RCM Pharma … “brevemente teremos a possibilidade de dispor de novos fármacos orais, nomeadamente o Fumarato de Dimetilo, a Teriflunamida e o Laquinimod, assim como de vários anticorpos monoclonais, entre eles o Daclizumab, o Ocrelizumab e o Alemtuzumab. |
 iStockAnalyst (press release) |
Abbvie, Inc: Steady Humira = Steady ABBV
iStockAnalyst (press release) Daclizumab for Relapsing Remitting Multiple Sclerosis: A Phase III candidate. Effective but well behind very good new oral options (e.g. Novartis’ Gilenya) that have similar efficacy. However, Daclizumab could be even more convenient as a once-monthly … |
Acceleron and Shire Conclude Collaboration on ACE-031PipelineReview.com (press release)CAMBRIDGE, MA, USA I May 2, 2013 I Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, today reported…
Intas launches Mabtas, a biosimilar version of Rituximab – PharmaBiz.compharmabiz.comIntas Pharmaceuticals Ltd. has launched Mabtas, a biosimilar version of Rituximab competent in treating diseases characterized by excessive numbers of B cells, overact…
Release Date: April of 2013PipelineReview.com (press release)The present Competitive Intelligence Report about Antibody-Drug Conjugates (ADC) / Immunoconjugates provides a competitor evaluation in the field of tumor targeting antibodies conjugated via …
Biogen Idec – Too High Too Fast?Seeking AlphaDaclizumab-HYP Phase III data readout expected in 2014. It is also for relapsing forms of MS. Biogen also filed for approval with FDA for Hemophilia Factor 8 for A and 9 for B, based on significant Phase III…
Nanotechnology News (press release)Nanocomposites Used in Measurement of Human Serum AntibodiesNanotechnology News (press release)Our NanoNews Digest Sponsors Heifer International · Wikipedia Affiliate Button · Home > Press > Nanoco…